Single-blind, non-randomised, single-group repeated-measures study (n=15) testing IM 5‑MeO‑DMT (3, 6, 9 mg) and saline placebo across four sessions to assess MEG/fMRI markers and wellbeing.
Fifteen healthy volunteers will attend four dosing days spaced two weeks apart in a single-group, non-randomised, single-blind design; each session involves a single IM administration of 5‑MeO‑DMT (3 mg, 6 mg or 9 mg) or inactive saline.
Primary assessments are MEG-derived frequency oscillatory power bands (eyes closed) and post-acute fMRI functional connectivity measured ~90 minutes post-dose (12-minute resting-state MEG and 6-minute anatomical/functional MRI acquisitions).
Single-group repeated measures: each participant receives IM 5‑MeO‑DMT (3 mg, 6 mg, 9 mg) and inactive saline placebo across four sessions.
Active doses 3 mg, 6 mg, 9 mg administered across separate sessions.
Inactive saline placebo administered in one session.